Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Non-randomized Phase II Trial of Cetuximab in Combination With Irinotecan and 5-FU/FA for Patients With Metastatic Gastric Cancer

NCT01123811 is registered in ClinicalTrials.gov with Johannes Gutenberg University Mainz as lead sponsor.

NCT NCT01123811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01123811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Non-randomized Phase II Trial of Cetuximab in Combination With Irinotecan and 5-FU/FA for Patients With Metastatic Gastric Cancer
Lead sponsor
Johannes Gutenberg University Mainz
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2006
Completion date
May 31, 2010
Enrollment
45 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of stomach or esophagogastric junction